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Background
Opioid receptors belong to the rhodopsin subclass
within the superfamily of G protein-coupled receptors
(GPCR), which are characterized by the presence of
seven transmembrane (7TM) helices. They interact with
morphine and related opioid alkaloids as well as with
endogenous opioid peptides. There are three main types
of opioid receptors (μ, δ, ), which are differently impli-
cated in opioid function. Ligands specifically targeting
each opioid receptor type are of high interest both as
research tools and potential therapeutic agents. Activa-
tion of the μ opioid receptor produces many other
effects, besides its main involvement in pain control,
including immunomodulation, respiratory depression,
constipation, tolerance and physical dependence. With
the lack of an experimental 3D structure of the μ opioid
receptor, discovery of 3D pharmacophores for the recep-
tor that can explain the activity of a series of ligands
represents an important approach in drug discovery.
Materials and methods
A new ligand-based pharmacophore model for the μ
opioid receptor was generated using the LigandScout
program. A database consisting of morphinan deriva-
tives was generated to provide the base for virtual
screening and validation studies. Opioid receptor bind-
ing activity data earlier published by our group were
included in this in-house opioid library and a general
structure-activity relationship for morphinan com-
pounds was established.
Results
A merged feature ligand-based pharmacophore model
for the μ opioid receptor was generated using a highly-
active training set of morphinans (in-house opioid
library). The model was optimized, validated and was
s h o w nt ob ea b l et oi d e n t i f yh i g h l ya c t i v eμ opioid
ligands within a certain range, and excellent enrich-
ments were achieved. The pharmacophore model indi-
cated that the important features for the binding activity
with the μ receptor are the presence of at least three
hydrogen bond acceptors, one aromatic ring and one
positive ionisable feature.
Conclusions
The availability of the present pharmacophore model is
expected to provide a more rational hypothetical picture
of the primary chemical features responsible for activity,
to be a valuable tool for 3D virtual screening and thus
to facilitate the design of novel active candidates target-
ing the μ opioid receptor.
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